Biogen Idec Increases Revenue 18% to $1.4 Billion in the Second Quarter MarketWatch (press release) ... global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase 3 A-LONG and B-LONG trials for the long-lasting blood factors as well as the Phase 3 DECIDE study of daclizumab ... |
